Efficacy of daily single dose rifaximin for the prevention of hepatic encephalopathy in liver cirrhosis patients as compared to twice daily dosing.

Trial Profile

Efficacy of daily single dose rifaximin for the prevention of hepatic encephalopathy in liver cirrhosis patients as compared to twice daily dosing.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top